1Luc G, Bard J M, Arveiler D, et al. Lipoprotein (a) as a predictor of coronary heart disease: The PRIME Study. Atherosclerosis, 2001,163(2):377-384.
2Seman L G, Deluca C, Jenner J L,et al. Lipoprotein (a)-cholesterol and coronary heart disease in the Framingham Heart Study. Clin Chem, 1999,45(7):1039-1046.
3Lundstam U, Herlitz J, Karlsson T, et al. Serum lipids, lipoprtein (a) level, and apolipoprotein(a) isoforms as prognostic markers in patients with coronary heart disease. J Intern Med, 2002,251(2):111-118.
4Marcovina S M, Hegele R A, Koschinsky M L. Lipoprotein (a) and coronary heart disease risk. Curr Cardiol Rep,1999,1(2):105-111.
5Angles C E. Structural basis for the pathophysiology of lipoprotein(a) in the athero-thrombotic process. Braz J Med Biol Res,1997,30(11):1271-1280.
6Maeda S, Abe A, Seishima M, et al. Transient change of serum lipoprotein (a) as an acute phase protein. Atherosclerosis, 1989,78(1):145-150.
7Greory Y H, Gordon D L. Fibrin D-dimer: A useful marker of thrombogenesis? Clini Sci,1995(89):205-214.
7Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and pros- tacyclin metabolites in pulmonary hypertension[ J]. N En- gl J Med,1992,327:70 -75.
8Giaid A, Yanagisawa M, Langleben D, et al Expression of endothelin-1 in the lungs of patients with pulmonary hy- pertension[ J ]. N Engl J Med, 1993,328 ( 24 ) : 1732 - 1739.
9Steward D J, Levy RD, Cernacek P. Increased plasma en- dothelin-1 in pulmonary hypertension marker or mediator of disease? [ J ]. Am Intern Med, 1991,114:464 - 469.
10Pietra GG, Capron F, Stewart S, et al. Pathologic assess- ment of vasculopathies in pulmonary hypertension [ J ]. J Am Coli Cardio1,2004,43( 12 Suppl S) :25S- 32S.
